Showing 561 - 580 results of 586 for search '"Peking Union Medical College"', query time: 0.10s Refine Results
  1. 561

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  2. 562
  3. 563
  4. 564
  5. 565
  6. 566
  7. 567

    Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies by Cui Y, Liu X, Feng S

    Published 2025-02-01
    “…Yuqing Cui,1,2 Xin Liu,1,2 Sizhou Feng1,2 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People’s Republic of China; 2Tianjin Institutes of Health Science, Tianjin, 300020, People’s Republic of ChinaCorrespondence: Sizhou Feng, Email doctor_szhfeng@163.comPurpose: Since the publication of the 2011 Infectious Diseases Society of America (IDSA) guidelines for empirical treatment of febrile neutropenia (FN), there have been significant shifts in pathogen profiles and emerging challenges in treatment. …”
    Get full text
    Article
  8. 568
  9. 569
  10. 570
  11. 571
  12. 572
  13. 573
  14. 574
  15. 575
  16. 576

    TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma by Wang W, Zhang Q, Cui Y, Zhang S, Li B, Xia T, Song Y, Zhou S, Ye F, Xiao W, Cao K, Chi Y, Qu J, Zhou G, Chen Z, Zhang T, Chen X, Ju S, Wang YC

    Published 2025-01-01
    “…Weilang Wang,1,* Qi Zhang,2,* Ying Cui,1,* Shuhang Zhang,1 Binrong Li,1 Tianyi Xia,1 Yang Song,3 Shuwei Zhou,1 Feng Ye,4 Wenbo Xiao,5 Kun Cao,6 Yuan Chi,7 Jinrong Qu,8 Guofeng Zhou,9,10 Zhao Chen,11 Teng Zhang,12 Xunjun Chen,13 Shenghong Ju,1 Yuan-Cheng Wang1 1Department of Radiology, Zhongda Hospital, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, School of Medicine, Southeast University, Nanjing, 210009, People’s Republic of China; 2Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China; 3MR Scientific Marketing, Siemens Healthineers Ltd, Shanghai, People’s Republic of China; 4Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 5Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 6Department of Radiology, Peking University Cancer Hospital and Institute, Beijing, People’s Republic of China; 7Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China; 8Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, People’s Republic of China; 9Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 10Shanghai Institute of Medical Imaging, Shanghai, People’s Republic of China; 11Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 12Institute for Artificial Intelligence in Medicine, School of Artificial Intelligence, Nanjing University of Information Science and Technology, Nanjing, People’s Republic of China; 13Department of Radiology, The People’s Hospital of Xuyi County, Huaian, Jiangsu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yuan-Cheng Wang, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Ding Jia Qiao Road, Nanjing, Jiangsu, 210009, People’s Republic of China, Tel +086 25 83272121, Fax +086 25 83311083, Email yuancheng_wang@seu.edu.cnPurpose: To develop and validate a predictive model for predicting six-month outcome by integrating pretreatment MRI features and one-month treatment response after TACE.Methods: A total of 108 patients with 160 hCCs from a single-arm, multicenter clinical trial (NCT03113955) were analyzed and served as the training cohort. …”
    Get full text
    Article
  17. 577
  18. 578
  19. 579
  20. 580